IP Library Granted Patent US 7,067,511
Granted Patent B2
US 7,067,511 · App. 10/021,213 · Granted Jun 27, 2006

Pyrrolobenzodiazepines

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,067,511
App. No.
10/021,213
Granted
Jun 27, 2006
Kind
B2
Abstract

Compounds of the formulae Ia and Ib: wherein: A is CH 2 , or a single bond; R 2 is selected from: R, OH, OR, CO 2 H, CO 2 R, COH, COR, SO 2 R, CN; R 6 , R 7 and R 9 are independently selected from H, R, OH, OR, halo, amino, NHR, nitro, Me 3 Sn; and R 8 is selected from H, R, OH, OR, halo, amino, NHR, nitro, Me 3 Sn, where R is as defined above, or the compound is a dimer with each monomer being the same or different and being of formula Ia or Ib, where the R 8 groups of the monomers form together a bridge having the formula —X—R′—X— linking the monomers, where R′ is an alkylene chain containing from 3 to 12 carbon atoms, which chain may be interrupted by one or more hetero-atoms and/or aromatic rings and may contain one or more carbon-carbon double or triple bonds, and each X is independently selected from O, S, or N; except that in a compound of formula Ia when A is a single bond, then R 2 is not CH═CH(CONH 2 ) or CH═CH(CONMe 2 ). Other related compounds are also disclosed.

Claims (7)

1. A compound of the formula:

wherein p is 3.

2. A method of treatment of lung, colon, CNS, ovarian or breast carcinomas or melanomas of the human or animal body comprising administering to such a subject a therapeutically effective amount of a compound according to claim 1 .

3. A method of treatment of a cisplatin-refractory ovarian carcinoma of the human or animal body comprising administering to such a subject a therapeutically effective amount of a compound according to claim 1 .

4. A method of inhibiting the growth of human ovarian cisplatin-refactory cells which method comprises treating said cells with a compound according to claim 1 .

5. A pharmaceutical composition comprising a compound of formula:

wherein p is 3 and a pharmaceutically acceptable excipient, carrier, buffer or stabilizer.

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE POSTAL CODE OF THE ASSIGNEE PREVIOUSLY RECORDED AT REEL: 036932 FRAME: 0278. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT . Recorded Apr 11, 2017
From: SPIROGEN SÀRL
To: MEDIMMUNE LIMITED
Reel/Frame 042242/0389 →
CONFIRMATORY ASSIGNMENT Recorded Oct 23, 2015
From: SPIROGEN SÀRL
To: MEDIMMUNE LIMITED
Reel/Frame 036932/0278 →